Continue Reading
Full article on Unknown
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
Market Intelligence Analysis
AI-Powered
Why This Matters
MediciNova has completed patient enrollment for its Phase 2 clinical trial evaluating MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatment.
Market Impact
Market impact analysis based on bullish sentiment with 73% confidence.
Sentiment
Bullish
AI Confidence
73%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led
Original article published by
Unknown
on December 18, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.